IMPLANON Application Scope

IMPLANON® (etonogestrel implant) is a long-acting, reversible progestin-only contraceptive implanted subdermally for up to 3 years to prevent pregnancy.

It is not suitable for women with estrogen-sensitive conditions and does not protect against HIV or other STIs.

IMPLANON Characteristics

Ingredients: Etonogestrel (68 mg) contained in a single rod of non-biodegradable ethylene-vinyl acetate (EVA) copolymer.
Properties: Flexible, off-white rod (4 cm × 2 mm) releasing ~60–70 µg/day in week 5–6, decreasing to ~25–30 µg/day by year 3.
Packaging Specification: Preloaded in a sterile disposable applicator; individual units blister-packed.
Storage: Store at controlled room temperature (15–30 °C), ideally at 25 °C. Keep in original blister and protect from light.
Expiry Date: Refer to labeling; typically up to 3–5 years when stored properly.
Executive Standard: Compliance with global pharmacopeial and regulatory standards for contraceptive implants. (Not explicitly cited; implied by regulatory approvals.)
Approval Number: Products approved in multiple countries since 1998; regulatory details vary by region.
Date of Revision: Specific revision dates not listed; refer to current label for updates.
Manufacturer: Originally developed by N.V. Organon (Merck subsidiary); marketed as Implanon, later replaced by radiopaque Nexplanon.

Guidelines for the Use of IMPLANON

Dosage and Administration: Designed for subdermal insertion of one implant in the inner side of the upper non-dominant arm. Remains effective up to 3 years; removal at or before year three is necessary to maintain contraceptive efficacy.

Administration: Placed using preloaded sterile applicator; insertion by trained healthcare provider; ensure implant is palpable and correctly placed.

Missed Dose: Not applicable—implant continuously releases hormone without user input.

Adverse Reactions:
- Common Adverse Reactions (≥5% and >3% higher than placebo):
  - Injection site reactions (19%)
  - Decreased platelet count (12%)
  - Arthralgia (9%)
- Serious Adverse Reactions:
  
  Hypersensitivity reactions, including bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias.
  
  Contraindications: Known or suspected breast cancer or other progestin-sensitive malignancies; hypersensitivity to components.
  
  Precautions: Proper insertion required to prevent complications; follow-up for abnormal bleeding; removal issues addressed particularly in deep or migrated implants.

IMPLANON Interactions

Systemic drug interactions minimal due to local release; enzyme induction (e.g., CYP3A4 inducers) may reduce etonogestrel levels and contraceptive efficacy.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.